SCYNEXIS: Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3

 

• Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in patients treated with ibrexafungerp.
   
• All-cause mortality analysis shows 94.6% survival 30 days post-therapy in patients with invasive candidiasis or candidemia who were treated with ibrexafungerp.

https://www.biospace.com/article/releases/scynexis-presents-positive-interim-data-of-oral-ibrexafungerp-for-severe-fungal-infections-from-ongoing-phase-3-furi-study-during-idweek-2022/